Objective
We hypothesize that Fcμ acts through a receptor called FcμR, found on antigen-presenting cells and T cells. By engaging this receptor, Fcμ enhances the clearance of dying cells, restores healthy B-cell regulation, stabilizes regulatory T cells, and suppresses harmful autoimmune T-cell activity. Together, these actions prevent the return of autoimmunity, support the survival and function of transplanted islets, and promote durable β-cell–specific immune tolerance. This represents a paradigm shift from traditional immunosuppressive strategies, offering a targeted, measurable, and scalable pathway suitable for clinical translation. The objective of this project is to advance an immune tolerance-restoring treatment for type 1 diabetes (T1D) using naturally occurring antibody IgM and its therapeutic fragment, Fcμ. The following aims directly support this objective by defining how Fcμ restores immune tolerance, determining its therapeutic effectiveness, and establishing the safety and development parameters required for clinical translation. Aim 1 will define how Fcµ works and identify biomarkers—measurable signals in blood or tissues—that track its activity. This includes defining its distribution in the body, engagement with immune cells, and FcµR-dependent immune reprogramming; testing whether Fcµ can halt or reverse diabetes; mapping tolerance-associated protein signatures; measuring FcµR-dependent regulatory T-cell changes; analyzing dendritic-cell (an APC) behavior; and examining B-cell subset shifts, including NF-κB p65 signaling, an internal switch that regulates inflammation. Aim 2 will test whether Fcμ improves islet transplant outcomes and whether Fcμ-conditioned regulatory T cells can prevent diabetes when transferred into immunodeficient animals that develop T1D after receiving diabetic immune cells, establishing its effectiveness in both transplantation and autoimmune settings. Aim 3 will evaluate the purity, stability, safety, and pharmacokinetics of Fcμ, including storage stability, receptor-binding activity, delivery-route pharmacokinetics, repeat-dose safety, and determination of the “no observed adverse effect level,” to enable future clinical advancement.
Background Rationale
Type 1 diabetes (T1D) is a lifelong autoimmune disease in which the immune system mistakenly destroys the pancreas’s insulin-producing β cells, resulting in complete insulin dependence and a high risk of long-term complications. Nearly two million Americans live with T1D, and millions more worldwide are affected. Once β cells are destroyed, no therapy can reliably stop the autoimmune attack or restore the body’s natural insulin-producing ability, making T1D a major public health and economic burden. Treatments that target the immune system—whether temporarily removing certain immune cells, broadly suppressing immunity, or attempting to retrain immune responses with specific antigens—are effective only while being administered and often increase susceptibility to infection or other adverse effects. Importantly, none of these approaches correct the underlying dysfunction in B cells, an immune cell subset that produces antibodies and helps direct immune responses. This B-cell dysregulation plays a central role in the development and progression of T1D, yet remains largely unaddressed by existing and emerging therapies. Effective options for people in the earliest stages of T1D, or for those at high risk of developing the disease, are also extremely limited. Even pancreas or islet transplantation—the only intervention capable of replacing β cells—faces major challenges, like early inflammatory injury to the graft, immune rejection, and recurrence of autoimmunity. These limitations underscore the need for a benign, short-course therapy that can restore durable immune tolerance without compromising normal immunity. Our research introduces a therapeutic approach built on a naturally occurring antibody called immunoglobulin M (IgM), which plays a fundamental role in maintaining healthy immune balance. We have shown that IgM can prevent T1D, halt disease progression, reverse new-onset diabetes, and dramatically improve the survival of transplanted islet cells—all without chronic immunosuppression or immune cell deletion. When given with a minimal dose of islets, IgM also reverses established diabetes. It accomplishes this by calming inflammation across multiple immune pathways, stabilizing regulatory T cells, restoring healthy B-cell behavior, reducing insulin-targeting autoantibodies, and enhancing clearance of dying cells that otherwise drive immune activation. Preliminary proteomic and cellular studies suggest that IgM coordinates both early (“innate”) and later (“adaptive”) arms of the immune system, and pharmacokinetic and stability studies support its feasibility as a therapeutic product. We identified a specific portion of the IgM molecule—called Fcμ—as the critical driver of these immune-restoring effects. By interacting with its receptor found on immune cells, Fcμ improves clearance of dying cells, resets B-cell activity, strengthens regulatory T cells, and reduces harmful autoimmune T-cell responses. Together, these effects prevent autoimmune recurrence, support transplanted islets, and promote long-lasting, β-cell–specific immune tolerance. This represents a major departure from traditional immunosuppressive strategies, offering a targeted approach that is measurable, reproducible, and scalable for clinical development. The substantial global burden of T1D reinforces the urgency of developing such therapies. About 9.5 million people worldwide live with T1D, with incidence rising rapidly. T1D causes nearly 174,000 deaths each year, often due to delayed diagnosis. The economic costs are enormous: the T1D market alone is expected to more than double—from $34.87 billion in 2024 to $74.03 billion by 2034—and diabetes-related expenses in the United States already exceed $412 billion annually. This proposal therefore aims to optimize Fcμ as the first-in-class, multi-mechanistic biologic capable of preventing, halting, and potentially reversing autoimmune diabetes. Fcμ is benign, durable, and scalable, and complements other strategies such as cell-based therapies and antigen-specific approaches while addressing fundamental gaps they cannot fill. No existing or emerging therapy matches its breadth of action, safety profile, or its translational potential to restore durable, β-cell–specific immune tolerance and achieve a cure for T1D.
Description of Project
Type 1 diabetes (T1D) is an autoimmune disease in which the immune system destroys the pancreas’s insulin-producing β cells, resulting in loss of glucose control, lifelong insulin dependence, and a high risk of long-term complications. At present, no therapy can reliably stop the autoimmune attack or restore the body’s natural insulin-producing capacity. Immune-directed treatments—whether temporarily removing immune cells, broadly suppressing immunity, or retraining the immune system with specific antigens—offer short-term benefit, require continuous use, and increase vulnerability to infection and other adverse effects. Importantly, none of these approaches correct the underlying dysfunction in B cells (immune cells that produce antibodies and act as antigen-presenting cells (APCs) that guide immune responses) that contributes to T1D development and progression. Effective treatments for people in the earliest disease stages or at high risk of developing T1D remain extremely limited. Even curative pancreas or islet transplantation faces major challenges: early inflammation that damages transplanted tissue, graft rejection, and recurrence of autoimmunity. These limitations highlight the urgent need for a benign, transient therapy that restores lasting immune tolerance. Our research introduces a therapeutic strategy based on a naturally occurring antibody known as immunoglobulin M (IgM), which plays a fundamental role in maintaining immune balance. We have shown that IgM prevents the onset of T1D, halts its progression, and reverses newly diagnosed diabetes in mouse models. When combined with a marginal dose of transplanted islet cells, IgM also reverses established diabetes. IgM promotes β-cell recovery, reduces inflammation across immune pathways, and increases an immune subset called regulatory T cells that are essential for preventing autoimmune reactions. It re-establishes healthy B-cell regulation, reduces insulin-targeting autoantibodies, improves clearance of dying cells, and enhances survival of transplanted islets without chronic immunosuppression. Preliminary proteomic and cellular studies indicate that IgM coordinates both early and later immune processes, and pharmacokinetic and stability studies support its therapeutic potential. We have identified the Fcμ portion of IgM as the key driver of these beneficial effects. Fcμ alone prevents diabetes in mice, improves islet graft success in IgM-deficient animals, and expands regulatory T cells. We propose that Fcμ interacts with FcμR, a receptor on APCs and T cells. Through this receptor, Fcμ enhances clearance of dying cells, re-establishes B-cell regulation, stabilizes regulatory T cells, and quiets autoimmune T cells. These combined actions prevent autoimmune recurrence, support transplanted islets, and promote β-cell-specific immune tolerance—a major departure from traditional immunosuppressive approaches—thereby offering a pathway that is measurable, reproducible, and scalable for clinical development. Aim 1 will define how Fcµ works and identify biomarkers—measurable signals in blood or tissues—that track its activity. It will define its distribution in the body, engagement with immune cells, and FcµR-dependent immune reprogramming; test whether Fcµ can halt or reverse diabetes; map tolerance-associated protein signatures; measure FcµR-dependent regulatory T-cell changes; analyze dendritic-cell (an APC) behavior; and examine B-cell subset shifts, including NF-κB p65 signaling, an internal switch that regulates inflammation. Aim 2 will test whether Fcμ improves islet transplant outcomes, and whether Fcμ-conditioned regulatory T cells can prevent diabetes when transferred into immunodeficient animals that develop T1D after receiving diabetic immune cells, establishing its effectiveness in transplant and autoimmune settings. Aim 3 will evaluate the purity, stability, safety, and pharmacokinetics of Fcμ, including storage stability, receptor-binding activity, delivery-route pharmacokinetics, repeat-dose safety, and determination of the “no observed adverse effect level,” to support clinical advancement. With its ability to support lasting immune tolerance, act across multiple immune pathways, and maintain a strong safety profile, Fcμ represents a pioneering therapeutic approach with the potential to transform the treatment of autoimmune diabetes.
Anticipated Outcome
We anticipate a clear understanding of how Fcμ therapy restores healthy immune function by identifying the specific immune pathways it engages. These mechanistic insights will be paired with rigorous proof of therapeutic benefit, including evidence that Fcμ can halt or even reverse autoimmune diabetes and significantly improve the survival and function of transplanted islet cells using validated disease models. Biomarkers that can predict the onset or recurrence of T1D and assess treatment efficacy will also be identified. This work will generate essential safety and development data, defining Fcμ’s purity, stability, biological behavior, and the dose levels that do not produce adverse effects. In parallel, Fcμ will be optimized for clinical translation by refining its delivery and manufacturability to support future development efforts. We anticipate these studies will advance Fcμ as a first-in-class, tolerance-restoring biologic that reestablishes immune regulation through endogenous FcμR-dependent pathways—rather than broad immunosuppression or immune cell depletion—providing durable protection across multiple stages of T1D and in post-transplantation settings, where preventing autoimmune relapse is critical. We expect to position Fcμ as a strong candidate for future clinical studies aimed at preventing, stopping, or reversing type 1 diabetes. The anticipated outcome of this research is the development of a safe, durable, and scalable biologic that complements cell-based and antigen-specific approaches while addressing fundamental gaps that no current or emerging therapies have addressed.
Relevance to T1D
This proposal directly addresses some of the most urgent and longstanding unmet needs in type 1 diabetes (T1D). Currently, no therapy can reliably stop the autoimmune destruction of β cells, restore natural insulin production, or protect transplanted islets without the heavy costs of chronic immunosuppression. Despite major advances in glucose monitoring, insulin delivery, and transplantation, people with T1D still lack a safe and durable immune-based therapy capable of preserving or restoring their own insulin-producing cells. IgM-Fcμ therapy introduces an entirely new class of treatment designed to retrain the immune system rather than silence it. Instead of broadly suppressing immunity, Fcμ engages the body’s natural tolerance pathways to correct the core immune dysfunction that drives T1D. This creates the possibility of long-lasting, β-cell–specific immune tolerance—a fundamentally different and safer approach than anything available today. Both full-length IgM and its Fcμ fragment represent a pioneering therapeutic breakthrough that can benefit people across the entire spectrum of T1D. Fcμ therapy has the potential to prevent disease onset in those at the earliest stages or at high risk, halt disease progression, reverse T1D in people with new-onset, and protect islet grafts in individuals receiving islet transplants. It also reverses established disease when administered with a minimal dose of islet transplant. By restoring healthy immune regulation rather than weakening protective immunity, Fcμ could significantly change outcomes for every major group affected by T1D.
Fcμ therapy offers several advantages where current therapies fall short:
Durability: establishes long-lasting immune tolerance after only short-course treatment, rather than providing temporary suppression.
Breadth: simultaneously regulates multiple immune cell subsets—such as B cells (which produce antibodies and help guide immune responses), regulatory T cells (which suppress harmful autoimmune activity), and antigen-presenting cells (which direct how the immune system responds to threats)—along with broader inflammatory circuits that shape autoimmune behavior.
Safety: avoids chronic immunosuppression, does not deplete immune cells, and does not increase infection risk.
Translational range: shows activity across prevention, progression arrest, new-onset T1D reversal, and post-transplant protection; it also protects against established diabetes when administered together with a minimal-dose islet transplant.
Together, these attributes position Fcμ as a first-in-class, tolerance-restoring, multi-mechanistic biologic that is benign, durable, and scalable. This therapy has the potential not only to modify the course of T1D, but to provide a path toward preventing, halting, and permanently reversing autoimmune diabetes. No existing or emerging therapy matches its breadth of action, its safety profile, or its capacity to restore the durable, β-cell–specific immune tolerance required to cure T1D.